21st International Conference on Emergency Medicine 2022

14 – 19 June

Hybrid Conference I Melbourne Convention and Exhibition Centre

21st International Conference on Emergency Medicine

14 – 19 June 2022

Hybrid Conference
Melbourne Convention and Exhibition Centre

21st International Conference on Emergency Medicine 2022

14 – 19 June

Hybrid Conference I Melbourne Convention and Exhibition Centre
PARTNER PROGRAM SPONSOR
0700-0815
SATURDAY 18 JUNE

BREAKFAST SESSION 7

Decisions with DOAC’s: new data, old challenges

Emergency Medicine is all about decisions: what to do, what not to do and who to call. During this symposium Dr Parks will take us through some of his cases that illustrate the challenges of decision making when faced with patients who are either on a DOAC, or who need a DOAC. Dr Ho will lend his hematology expertise to the conversation, and together with your questions, an interactive session is promised. Topics the experts will cover include: new guidelines from ISTH on use of DOACs in obese patients, how covid-19 has shifted PE management to the outpatient setting, and the risk-benefit of anticoagulation in a frail falls patient who is at risk of a stroke.

Speakers: Dr James Parks, A/Prof Prahlad Ho

Speaker: Dr James Parks

Dr James Parks currently works within Western NSW LHD as the Clinical Director for the vCare critical care and transport telehealth service and as the Medical Lead for Remote In-Home Monitoring. Clinical roles include more than a decade working as an Emergency Specialist in tertiary, metropolitan and regional NSW hospitals.

Previous roles include Director of Emergency Medicine for a metropolitan non-tertiary hospital, Director of Emergency Medicine Training and the provision of medical support for remote environments, major events and aeromedical retrieval.

 

Special interests include development of a variety of practical multi-professional clinical and human factors training programmes and in meeting the clinical challenges of rural, remote and austere environments.

Speaker: A/Prof Prahlad Ho

Dr Prahlad Ho is originally from Singapore and graduated with honours from the University of Melbourne. He completed his haematology training at the Austin and Northern Hospitals in Melbourne.

Dr Ho is currently the Divisional Director for Diagnostic and Outpatient Services & Cancer Services (Medical) at Northern Health. He was the inaugural Director of Northern Pathology Victoria and also a honorary haematologist at Alfred Health and the primary visiting haematologist at Northpark Private Hospital.

Dr Ho is actively involved in clinical research and has published in multiple international peer-reviewed journals. He completed his PhD through the University of Melbourne under a National Health and Medical Research Council (NHMRC)/Heart Foundation scholarship. He is currently an honorary/adjunct Senior Research Fellow at both the University of Melbourne as well as the Australian Centre of Blood Disease (ACBD), Monash University. He is the Head of the Haematology Research Unit at Northern Health and is the Principal Investigator in numerous malignant and non-malignant clinical trials. In this role, he supervises PhD and medical students as well as a number of postgraduate physician trainees His specific interest is investigating new biomarkers of thrombosis, specifically global coagulation assays.

The Bristol Myers Squibb-Pfizer Alliance is committed to driving education and awareness about atrial fibrillation and venous thromboembolism. With long-standing cardiovascular leadership, global scale and expertise in this field, the Alliance strives to implement global, research-driven approaches to illuminate and address the unmet needs around strokes related to non-valvular atrial fibrillation, which are often fatal or debilitating.1 Through collaborations with non-profit organizations, the Alliance aims to provide patients, physicians, and decision makers with the information they need to understand and take appropriate action on risk factors associated with stroke and other cardiovascular conditions. 

1 Ben Freedman, Tatjana S. Potpara, and Gregory Y H Lip, “Stroke prevention in atrial fibrillation,” The Lancet 388, no. 10046 (2016): , doi:10.1016/s0140-6736(16)31257-0. 

Vyaire Medical Inc. is a global company, headquartered in suburban Chicago, focused exclusively on supporting breathing through every stage of life. Established from legacy brands with a 65-year history of pioneering breathing technology, the company’s portfolio of integrated solutions is designed to enable, enhance, and extend lives.

At Vyaire, our team of 4000, pledges to advance innovation and evolve what’s possible to ensure every breath is taken to its fullest. Vyaire’s products are available in more than 100 countries and are recognized, trusted, and preferred by specialists throughout the respiratory community worldwide.

Vyaire has a long and proud history with emergency care throughout Australia and beyond. As the home of legacy brands including Vital Signs, AirLife, enFlow, GreenLight, bellavista, and many more, we are your trusted partner every step in delivering emergency care.

Come speak to Vyaire to learn more about our innovative solutions in ventilation and respiratory care, and blood and fluid management in the ED.

COMPANY

Insert Bio

NAME

Face placeholder

Insert Title

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.